LVCLFALGORAE PHARMACEUTICALS LTD.

About ALGORAE PHARMACEUTICALS LTD. (LVCLF)

ALGORAE PHARMACEUTICALS LTD. (LVCLF) is a Biotechnology company headquartered in Melbourne, VA, Australia whose shares trade over-the-counter on the Pink tier.

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions such as Parkinson's disease, obesity and migraine. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL produces nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. In a Phase IIb trial of NTCELL, there was not a statistically significant difference between the groups who received NTCELL and the placebo group at the 26-week study endpoint. However, at 24 months post-implant a clinically relevant effect was observed (<-6.45 points from baseline) in two of the three treatment groups. A Phase III clinical study with a larger number of patients is necessary to provide efficacy data to enable marketing approval from regulatory agencies. This would require a significant further investment. LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

Products and services

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions such as Parkinson’s disease, obesity and migraine. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL produces nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. In a Phase IIb trial of NTCELL, there was not a statistically significant difference between the groups who received NTCELL and the placebo group at the 26-week study endpoint. However, at 24 months post-implant a clinically relevant effect was observed (<-6.45 points from baseline) in two of the three treatment groups. A Phase III clinical study with a larger number of patients is necessary to provide efficacy data to enable marketing approval from regulatory agencies. This would require a significant further investment. LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

LVCLF key facts

Ticker symbol

LVCLF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Melbourne, VA, Australia

Country of incorporation

AU

Year of incorporation

2003

Employees

3

Estimated market cap

$10.80M (as of May 12, 2025)

Shares outstanding

1,687,394,731

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Quarterly Report (Mar 31, 2024)

ALGORAE PHARMACEUTICALS LTD. leadership

• David R Hainsworth — Executive Director
• Kristina Stanley — Accountant
• Jennifer Victoria Voon — Company Secretary

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with L